Charles River Laboratories International, Inc. (NYSE:CRL) Receives $255.65 Consensus Target Price from Brokerages

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have been assigned an average rating of “Moderate Buy” from the sixteen analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $255.6471.

A number of analysts recently issued reports on CRL shares. Morgan Stanley lifted their price objective on Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Mizuho set a $264.00 target price on Charles River Laboratories International in a research report on Monday, August 10th. CLSA downgraded Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target for the company. in a research note on Monday, July 20th. Barclays reiterated an “overweight” rating and set a $300.00 price target on shares of Charles River Laboratories International in a report on Wednesday, August 5th. Finally, Evercore reissued an “outperform” rating on shares of Charles River Laboratories International in a research note on Wednesday, August 5th.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $286.44 on Tuesday. The company’s 50 day moving average price is $226.86 and its 200 day moving average price is $191.58. Charles River Laboratories International has a 52 week low of $144.26 and a 52 week high of $288.88. The company has a market capitalization of $13.67 billion, a PE ratio of -59.06, a PEG ratio of 2.90 and a beta of 1.38. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company’s revenue was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Research analysts expect that Charles River Laboratories International will post 11.35 EPS for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other news, EVP Victoria L. Creamer sold 4,179 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the transaction, the executive vice president owned 30,051 shares in the company, valued at approximately $7,788,017.16. This trade represents a 12.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Birgit Girshick sold 6,500 shares of Charles River Laboratories International stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the completion of the sale, the chief executive officer directly owned 36,013 shares of the company’s stock, valued at approximately $10,080,038.70. The trade was a 15.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 129,817 shares of company stock valued at $31,774,935. Insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Charles River Laboratories International

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Charles River Laboratories International by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock worth $1,174,374,000 after buying an additional 47,432 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Charles River Laboratories International by 115.8% during the 4th quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after acquiring an additional 1,446,972 shares during the last quarter. State Street Corp increased its holdings in shares of Charles River Laboratories International by 2.2% during the 4th quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock valued at $373,364,000 after acquiring an additional 40,535 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Charles River Laboratories International by 14.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock valued at $285,001,000 after acquiring an additional 210,260 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Charles River Laboratories International by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company’s stock valued at $254,186,000 after acquiring an additional 9,756 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.